Document is current
Any future updates will be listed below
-
Authors
Cormier-Daire, Valerie https://orcid.org/0000-0002-2839-9856
AlSayed, Moeenaldeen
Alves, Inês
Bengoa, Joana
Ben-Omran, Tawfeg
Boero, Silvio
Fredwall, Svein
Garel, Catherine
Guillen-Navarro, Encarna
Irving, Melita
Lampe, Christian
Maghnie, Mohamad
Mortier, Geert
Sousa, Sérgio B.
Mohnike, Klaus
-
Funding
Funding for this research was provided by:
BioMarin Pharmaceutical
Ascendis pharma
QED therapeutics
- License Information
-
More Information
Article History
Received: 18 October 2021
Accepted: 14 July 2022
First Online: 27 July 2022
Declarations
:
: Not applicable
: Not applicable
: TB-O, CG, JB, MI, MDS, and CL and have no conflict of interest to declare. IA has received grants or research support from BioMarin and honoraria or consultation fees from BioMarin, Ascendis Pharma, QED Therapeutics and Kyowa Kirin. SBS has received grants or research support from Pfizer and Ascendis and honoraria or consultation fees from BioMarin, Ascendis and Kiowa Kirin. SB has received honoraria or consultation fee from BioMarin. VC-D is PI of clinical trials on achondroplasia sponsored by BioMarin, QED and Theracon-Pfizer. SF has received honoraria (paid to his institution) from BioMarin. EG-N has received grants or research support from BioMarin and Alnylam (paid to her institution) and honoraria or consultation fees from BioMarin, Alnylam, UCB and Takeda. MM has received grants or research support from Merck and Pfizer, and honoraria or consultation fees from Novo Nordisk, Merck, Pfizer, Ascendis, BioMarin and Sandoz . KM has received honoraria or consultation fees from BioMarin, QED Therapeutics and Roche. GM has received grants or research support from Pfizer and honoraria or consultation fees from BioMarin and Pfizer.
